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Methods

Nanomedicine is a type of nanotechnology used in the medical field to
limit the dosage amount and target drug delivery to specific cells.
Nanomedicines that are approved and used tend to be extremely
successful; however despite over a decade of research, only a limited
number of nanomedicines have advanced for clinical use. A possible
reason for the numerous nanomedicine failures is lack of easily
accessible information and research on previous nanomedicines. In this
project, we have compiled nanomedicine labeling information from the
Drugs@FDA website. We have extracted phrases/sentences from labels
relating to keywords on nanomaterial properties and drug profile
characteristics. In the future, we plan to incorporate discontinued
nanomedicines, nanomedicines on the market, and nanomedicines in
different clinical trial phases. By compiling the descriptions and
contents of a set of specific nanomedicines, a machine learning program
could be developed to comb through literature and automatically
identify similar nanomedicine related entities. Our research works to
provide an easier and quicker method to obtain specific information on
approved nanomedicines.

Our initial database was based off of the work by Schutz et al. [3]. Figure 3
shows our Excel spreadsheet and consists of data collected from this paper. The
Drugs@FDA website has been our primary source for retrieving nanomedicine
labeling information. We extracted relevant data from the label information,
which consisted of entities in the form of a phrase/sentence relating to
nanomaterial properties and drug profile characteristics. These entities
specifically included the trade name, phase, platform, surface coating,
nanoparticle, max concentration, time to max concentration, generic/other name,
company, indication, clearance, volume of distribution, active ingredient, size,
route of administration, dose, dose form, plasma half life, and elimination half
life. After the data was extracted, the sentences containing this data were placed
into a separate Excel spreadsheet as shown in Figure 4. Figure 3 contains the
entire database that was updated and filled with information received from the
labeling documents during this project. The data was then analyzed to reveal
any potential trends.

Introduction

Figure 2. Illustration of a magnetic
nanoparticle’s “core-shell” structure.
This example has a iron oxide core,
which is common among magnetic
nanoparticles. [Image source: Ref. 2]

Figure 6. Prevalence
of the different
platforms each
nanomedicine
contained.
Liposomes were the
top platform used
followed by
Nanoparticles

After our thorough research and analysis of each nanomedicine, we
were able to group and categorize the drugs based on their platforms
and indications. When categorizing these characteristics we found
different trends and correlations. There were seven total nanomedicines
that had the indication of antineoplastic agents (medicines that target
cancerous cells). Out of the seven antineoplastic nanomedicines, six had
the platform of either a liposome or micelle. While liposomes and
micelles share many similar qualities, the structure remains as the
predominant difference. Micelles have a membrane monolayer, while
liposomes have a bilayer, signifying the liposomes are generally larger
in size. We conclude from this trend that encapsulating the drug in a
liposomes and micelles is a more successful drug delivery method
compared to attaching the drug to the surface of the particles. With
many new nanomedicines in the pipeline, this trend can easily change in
the future.

Conclusion
Figure 3. Screenshot of entire updated database.
Figure 4.
Screenshot
of our
sentence
extraction
excel
spreadsheet
for the
drug
Zevalin.

Results/Discussion

Figure 1. Different types of nanoparticles and ways they
can be modified and developed [Image source: Ref. 1]
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Abstract

We are used to information being readily accessible. When it comes to
the subject of nanomedicine that is no longer the case. The innovative
world of nanomedicine hasn’t evolved to its full advancing potential.
The application of nanotechnology for medical purposes has the
potential to greatly improve our world.
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Figure 5.
Prevalence of
the different
uses of FDA
approved
nanomedicines.
Antineoplastics
was the most
common.

As we continue our research, we plan to work with Dr. McInnes’s
research team to develop a system that automatically extracts
nanomedicine information. With the sentences we have collected and
categorized, the system will be able to search for entities within the label
information pdfs. With this entity extraction program, we will be able to
promptly gather the relevant nanomedicine information. The shortened
period for research allows for a clearer and quicker alternative in
viewing the relationships between the different types of nanomedicines.
Once the automation program is created, the current difficulties in
retrieving background research on nanomaterials will dramatically
decrease. This program will be able to extract entities from pdf files that
the user inputs. A separate program that automatically searches for
nanomedicine pdfs is also under development.
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